Rome

• Investigation the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants with Angelman Syndrome Ended
  2024-514797-45-00 3 2020-08-25 Angelman Syndrome (AS)
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscu … Ended
  2023-509935-23-00 4 2020-08-21 Duchenne Muscular Dystrophy
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended
  2024-512135-80-00 4 2020-07-13 Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarco
• Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended
  2022-502116-36-00 5 2020-07-10 Incurable/Non-metastatic Hepatocellular Carcinoma
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)
• A Phase 3 Study of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in AdultsUndergoin … Ended
  2024-514471-18-00 5 2020-05-13 Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri … Ended
  2023-504036-17-00 5 2020-05-07 Chronic Lymphocytic Leukemia (CLL)
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 5 2020-03-27 Retinopathy of prematurity
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• An extension study to learn about the long-term safety of fenfluramine hydrochloride for seizures in children and adults with rare seizure d … Ended
  2024-515680-61-00 5 2020-02-07 Dravet syndrome or Lennox-Gastaut syndrome
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors
• A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hyperoxaluria Type 1 Ended
  2023-503382-29-00 5 2020-01-20 Primary Hyperoxaluria Type 1 (PH1)
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• A Single-arm Study of Intrathecal SHP611 in Subjects with Metachromatic Leukodystrophy Ended
  2024-514402-31-00 4 2019-09-09 Late Metachromatic Leukodystrophy (MLD)

Showing 1,993–2,016 of 2,096 trials